Education
- PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
- MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
- BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
Research Summary
We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.Awards
- Forbeck Fellow, 2015
Recent Publications
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. Ascierto, PA, Fox, BA, Urba, WJ, Anderson, AC, Atkins, MB, Borden, EC, Brahmer, JR, Butterfield, LH, Cesano, A, Chen, DC et al.. 2020. J Immunother Cancer 8, .
doi: 10.1136/jitc-2020-000878PMID:32300051 - Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cohen, MA, Zhang, S, Sengupta, S, Ma, H, Bell, GW, Horton, B, Sharma, B, George, RE, Spranger, S, Jaenisch, R et al.. 2020. Cell Stem Cell 26, 579-592.e6.
doi: 10.1016/j.stem.2020.02.001PMID:32142683 - CD36 - the Achilles' heel of Treg cells. Horton, BL, Spranger, S. 2020. Nat. Immunol. 21, 251-253.
doi: 10.1038/s41590-020-0601-0PMID:32066948 - Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling. Nguyen, KB, Spranger, S. 2020. J. Cell Biol. 219, .
doi: 10.1083/jcb.201908224PMID:31816057 - Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). Ascierto, PA, Bifulco, C, Buonaguro, L, Emens, LA, Ferris, RL, Fox, BA, Delgoffe, GM, Galon, J, Gridelli, C, Merlano, M et al.. 2019. J Immunother Cancer 7, 332.
doi: 10.1186/s40425-019-0798-3PMID:31783779 - Tissue Site and the Cancer Immunity Cycle. Horton, BL, Fessenden, TB, Spranger, S. 2019. Trends Cancer 5, 593-603.
doi: 10.1016/j.trecan.2019.07.006PMID:31706507 - Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma. Trujillo, JA, Luke, JJ, Zha, Y, Segal, JP, Ritterhouse, LL, Spranger, S, Matijevich, K, Gajewski, TF. 2019. J Immunother Cancer 7, 295.
doi: 10.1186/s40425-019-0780-0PMID:31703593 - Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Bedognetti, D, Ceccarelli, M, Galluzzi, L, Lu, R, Palucka, K, Samayoa, J, Spranger, S, Warren, S, Wong, KK, Ziv, E et al.. 2019. J Immunother Cancer 7, 167.
doi: 10.1186/s40425-019-0640-yPMID:31272507 - Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Momin, N, Mehta, NK, Bennett, NR, Ma, L, Palmeri, JR, Chinn, MM, Lutz, EA, Kang, B, Irvine, DJ, Spranger, S et al.. 2019. Sci Transl Med 11, .
doi: 10.1126/scitranslmed.aaw2614PMID:31243150 - Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Bedognetti, D, Ceccarelli, M, Galluzzi, L, Lu, R, Palucka, K, Samayoa, J, Spranger, S, Warren, S, Wong, KK, Ziv, E et al.. 2019. J Immunother Cancer 7, 131.
doi: 10.1186/s40425-019-0602-4PMID:31113486